- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cate Lockhart, PharmD, PhD: Patient Acceptance of Biosimilars
Cate Lockhart, PharmD, PhD, discusses whether her work with the BBCIC will help encourage patient acceptance of biosimilars.
TranscriptWill the BBCIC’s work help with patient acceptance of biosimilars?
I think patients overall are much more sophisticated than people often give them credit for, you know, it’s people like me, people like you. So, I think not all of the patients are going to grasp maybe the nuances of what may come out of the research I’m doing with the BBCIC. But also, some of that comes down to how we communicate it. We can certainly put together a story that is appropriate for or is going to be meaningful for a patient or a patient group, or a patient advocacy organization for example, and we are engaging with patient organizations to help inform our research questions which is really helpful, so we’re answering the right questions for them to the extent possible within our constraints.
I think it’s both educating and providing evidence for physicians to make their decisions, as well as for patients, because the patient has a role in their healthcare obviously. Now more than ever patients are being a lot more in charge of their own healthcare. So, I don’t think we can necessarily split those or silo those. How we communicate our information and our science may be a little bit different depending on the audience, but I think its beneficial for everybody to understand their treatment and their treatment options.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
